Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (Q53021222)

10 May 2018

title

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (English)

1 reference

10 May 2018

1 reference

2

1 reference

10 May 2018

ESMO Guidelines Working Group

9

object named as

ESMO Guidelines Working Group

1 reference

10 May 2018

author name string

B Escudier

1

1 reference

10 May 2018

M Schmidinger

3

1 reference

10 May 2018

F Algaba

4

1 reference

10 May 2018

J J Patard

5

1 reference

10 May 2018

V Khoo

6

1 reference

10 May 2018

T Eisen

7

1 reference

10 May 2018

A Horwich

8

1 reference

10 May 2018

publication date

1 September 2014

1 reference

10 May 2018

published in

Annals of Oncology

1 reference

10 May 2018

volume

25 Suppl 3

1 reference

10 May 2018

page(s)

iii49-56

1 reference

10 May 2018

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

1 reference

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Systematic review of oncological outcomes following surgical management of localised renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Active surveillance of small renal masses: progression patterns of early stage kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Radiotherapy for renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU259

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU259

1 reference

10 May 2018

PubMed ID

25210086

1 reference

10 May 2018